Patients with angioimmunoblastic T-cell lymphoma (AITL) have a poor prognosis following conventional cytotoxic chemotherapy. With median remission rates of up to 50% achieved by combination chemotherapy, the probability of relapse is great, resulting in a median survival time of 36 months, with a range between 2 and 108 months.
1
The histomorphology of AITL is characterized by a prominent vascular component, 2 which is crucial for tumor growth, invasion and metastasis. 3 In a few patients with AITL not responding to conventional cytotoxic chemotherapy compounds with an antiangiogenetic effect, such as thalidomide, have been used and found to be effective to some extend. 4 We report here on a patient achieving complete remission as a result of single-agent treatment with the chimeric anti-VEGF monoclonal antibody bevacizumab (Avastin s ).
Case history
A 44-year-old female was admitted to our hospital after being treated for a suspected infection with high fever and dyspnea. The patient presented with lymphadenopathy, anemia, severe thrombocytopenia, bilateral pleural effusions, ascites and acute renal failure. Computer tomography (CT) showed hepatomegaly and cervical, thoracal and abdominal masses suspicious of lymphoma. Histopathological examination of an enlarged lymph node and bone marrow specimen showed AITL infiltration. Therefore, one cycle of standard cytotoxic chemotherapy according to the CHOEP scheme (cyclophosphamide 750 mg/ m 2 on day 1, etoposide 100 mg/m 2 on days 1-3, adriamycin 50 mg/m 2 on day 1, vincristine 1.4 mg/m 2 mg on day 1 and prednisone 100 mg on days 1-5) was administered. No response was observed, while aggravation of the respiratory insufficiency required intensive care and assisted ventilation. Owing to progressive disease, we administered one cycle of HAM chemotherapy (cytosine arabinoside 2000 mg/m 2 twice daily on days 1 and 2, mitoxantrone 10 mg/m 2 on days 2 and 3), resulting in a very good partial remission. Following the discharge from the intensive care unit, a second cycle was administered. Owing to the initially refractory and aggressive course of the disease, high-dose therapy with autologous peripheral blood stem cell transplantation was envisaged.
One week after discharge, the patient presented with bilateral swelling of the neck. A CT scan showed multiple enlarged cervical lymph nodes. In the light of this early relapse, a salvage therapy consisting of ICE (ifosfamide 5000 mg/m 2 on day 2, carboplatin AUC 5 on day 2 and etoposide 100 mg/m 2 on days 1-3) was given. Since a remission was obtained, high-dose chemotherapy according to the BEAM scheme (BCNU 300 mg/ m 2 on day 1, etoposide 200 mg/m 2 on days 2-5, cytosine arabinoside 200 mg/m 2 on days 2-5, melphalan 140 mg/m 2 on day 6) was administered. After 4 weeks, CT showed only residual lymphatic tissue and a decrease in the size of the spleen. Positron emission tomography was performed to evaluate the remission status of the patient. The results were ambiguous and not helpful to discriminate between vital lymphoma and fibrosis. Clinical chemistry indicated borderline values for LDH.
To consolidate the remission status, a therapy with the monoclonal anti-CD52 antibody alemtuzumab (Mab Campath s ) was initiated. Owing to a rapidly evolving leukopenia, therapy was discontinued shortly after dose escalation and no further maintenance therapy was given.
During the following weeks, abdominal ultrasound was performed regularly and revealed a gradually progressive Figure 1 CT imaging of the abdomen at the time of relapse showed enlarged para-aortal lymph nodes and splenomegaly (a). After eight cycles of bevacizumab, the size of the lymph nodes and the spleen went back to normal (b). disease with enlarged lymph nodes and splenomegaly. The patient developed nocturnal fever and dyspnea. Owing to elevated EBV and CMV titers, antiviral therapy was initiated leading to normalization of the titers. Owing to an increase of LDH (360 U/l) and worsening of thrombocytopenia (68 000/ml) and anemia (Hb 9.9 g/dl), a biopsy from an enlarged inguinal lymph node was obtained showing AITL infiltration again. Ubiquitous lymphadenopathy was present (Figure 1a ) and bone marrow specimen showed a 15% lymphoma infiltration (Figure 3d) .
Allogenic PBSCT was then taken into account but postponed due the high treatment-related risk.
Since VEGF expression in lymphatic tissue has been demonstrated to have negative prognostic impact on survival, a therapy with the monoclonal anti-VEGF antibody bevacizumab was initiated.
Treatment was well tolerated without any side effects. After eight cycles of bevacizumab (5 mg/kg bodyweight administered every 2 weeks), no residual lymphatic tissue was seen and the spleen went back to normal size (Figure 1b) .
LDH, hemoglobin and thrombocytes had returned to normal levels and leukocytes increased to 3700/ml.
At that time, a bone marrow biopsy was made showing normal histology without lymphoma infiltration (Figure 3e ).
Following this remarkable response, restaging was performed 6 month after the start of treatment with bevacizumab showing intrapulmonal lesions, which proved to be lymphoma. Following a salvage therapy with fludarabine, cyclophosphamide and the monoclonal anti-CD52 antibody alemtuzumab (Mab Campath s ), the patient is scheduled for a nonmyeloablative conditioning therapy and allogenic blood stem cell transplantation from an HLA-identical donor.
Pathological features
The histopathological examination of an inguinal lymph node revealed AITL (confirmed by Professor AC Feller, Referenzzentrum fü r Lymphknotendiagnostik-und Hämato-pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lü beck). The lymph node architecture was destructed and a moderate broadening of the paracortical zone was seen. There was a diffuse infiltration by a polymorphous population of small-to medium-sized lymphocytes with clear to pale cytoplasma (Figure 2a ; Giemsa) and prominent numerous arborizing blood vessels (Figure 2b and c; hematoxylin-eosin) in the paracortex. CD3 stained most of the medium to large lymphoid cells (Figure 2d ). Using the anti-VEGF monoclonal antibody (VG-1) (medac Diagnostika; dil. 1:500), cytoplasmatic staining of the lymphoid cells (Figure 2e ) and the endothelial cells (Figure 2f ) became evident. At the time of relapse, an inguinal lymph node showed AITL infiltration again. Immunostaining was positive for CD3 ( Figure 2g ) and VG-1 in the lymphoid cells (Figure 2h ). After eight cycles of bevacizumab treatment, lymphadenopathy had disappeared as observed by CT scans, thus no further lymph node excision was performed.
Figure 2
Histomorphology of the inguinal lymph nodes at the time of diagnosis (a-f) and at the time of relapse (g and h).
Correspondence
The initial bone marrow section showed an infiltration of 40% by the AITL (Figure 3a ; hematoxylin-eosin) with positive CD3 staining (Figure 3b ) and positive cytoplasmic staining for VG-1 (Figure 3c ) in the lymphoid cells. At the time of relapse, the histopathological examination of the bone marrow biopsy revealed an infiltration of 15% by the AITL with CD3-positive staining as well as cytoplasmic staining for VG-1 in the lymphoid cells (Figure 3d ). After eight cycles of bevacizumab, the bone marrow was free of lymphoma ( Figure 3e ).
Antiangiogenic approaches have been explored as a means to suppress malignant growth in solid tumors, leukemia and lymphoid malignancies. 5 Treatment with the monoclonal anti-VEGF antibody bevacizumab has proved to prolong survival of patients with solid tumors, but has not been used in patients with lymphoid malignancies. 6 Recently, it has been demonstrated that VEGF-A is expressed on both lymphoma cells and endothelial cells in angioimmunoblastic lymphoma. Increased levels of VEGF-A in lymphoma cells, as in endothelial cells, were related to extranodal involvement and short survival time.
In our patient, the lymph node specimen and the bone marrow areas with lymphoma infiltration showed expression of VEGF-A on lymphoma cells as well as on the endothelium of dystrophic microvessels suspicious for neovasculature. 7 After eight cycles of bevacizumab, histopathology of the bone marrow biopsy including VEGF staining revealed the disappearance of VEGF-expressing lymphoma cells and a decrease of bone marrow vascularization. VEGF blockage seems to exert its effects through inhibition of autocrine and paracrine VEGF-R1-and VEGF-R2-mediated pathways in lymphoma cells as it has been demonstrated in lymphoma xenografts. 8 The results of this monotherapeutic approach support the view that bevacizumab is an effective treatment option with excellent tolerance.
However, the transient nature of the response demonstrates the highly aggressive course of the disease, implying that the monoclonal antibody might be used in combination with a cytotoxic chemotherapy. 
